Barrow Hanley Mewhinney & Strauss LLC Continues to Hold Stake in Teva Pharm (TEVA)

August 11, 2017 - By Hazel Jackson

Barrow Hanley Mewhinney & Strauss Llc increased its stake in Teva Pharm (TEVA) by 22.15% based on its latest 2016Q4 regulatory filing with the SEC. Barrow Hanley Mewhinney & Strauss Llc bought 5.88 million shares as the company’s stock declined 15.11% while stock markets rallied. The institutional investor held 32.46M shares of the major pharmaceuticals company at the end of 2016Q4, valued at $1.18 billion, up from 26.57 million at the end of the previous reported quarter. Barrow Hanley Mewhinney & Strauss Llc who had been investing in Teva Pharm for a number of months, seems to be bullish on the $17.72B market cap company. The stock rose 0.06% or $0.01 reaching $17.2 per share. About 21.43 million shares traded or 7.47% up from the average. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has declined 41.70% since August 11, 2016 and is downtrending. It has underperformed by 58.40% the S&P500.

Barrow Hanley Mewhinney & Strauss Llc, which manages about $91.02B and $66.73B US Long portfolio, decreased its stake in Johnson & Johnson (NYSE:JNJ) by 459,030 shares to 11.88 million shares, valued at $1.37 billion in 2016Q4, according to the filing. It also reduced its holding in Sanofi (NYSE:SNY) by 1.94M shares in the quarter, leaving it with 29.38M shares, and cut its stake in Berkshire Hathaway Inc (BRKB).

More notable recent Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) news were published by: Foxbusiness.com which released: “ADRs End Mostly Higher; Alibaba, Teva Trade Actively” on August 07, 2017, also Investorplace.com with their article: “Why Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock Is Coming Back” published on July 17, 2017, Investorplace.com published: “Why Cyberark Software Ltd (CYBR), Teva Pharmaceutical Industries Ltd (ADR …” on July 14, 2017. More interesting news about Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) were released by: Foxbusiness.com and their article: “ADRs End Lower; Teva Trades Actively” published on August 03, 2017 as well as Investorplace.com‘s news article titled: “Will Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock Catch a Break?” with publication date: August 02, 2017.

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) Ratings Coverage

Among 27 analysts covering Teva Pharma (NYSE:TEVA), 7 have Buy rating, 2 Sell and 18 Hold. Therefore 26% are positive. Teva Pharma had 82 analyst reports since July 21, 2015 according to SRatingsIntel. The firm earned “Outperform” rating on Thursday, March 30 by Maxim Group. The firm has “Outperform” rating given on Monday, October 31 by Credit Suisse. Piper Jaffray maintained Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) on Friday, July 14 with “Hold” rating. Mizuho downgraded the stock to “Neutral” rating in Monday, October 24 report. The firm has “Neutral” rating given on Wednesday, November 16 by Mizuho. Mizuho downgraded Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) on Friday, February 10 to “Neutral” rating. On Thursday, July 13 the stock rating was maintained by Maxim Group with “Hold”. Leerink Swann maintained Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) rating on Tuesday, July 21. Leerink Swann has “Outperform” rating and $74 target. The stock of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has “Neutral” rating given on Friday, January 20 by JP Morgan. As per Tuesday, July 28, the company rating was maintained by Citigroup.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.